First Patient Enrolled in AFFIRM-205, a Ph III Study of LAE002 (afuresertib) + Fulvestrant for Treatment of Breast Cancer
“As shown in the results of Phase Ib study, the median PFS of afuresertib plus fulvestrant was 7.3 months. This is a significant improvement compared to the PFS data of 3-4 months for fulvestrant monotherapy. This combination therapy also demonstrated a favorable safety profile and the potential efficacy of AKT inhibitors to treat breast cancer, especially patients with PIK3CA/AKT1/PTEN alterations and HR+/HER2- locally advanced or metastatic breast cancer”, said Academician Binghe Xu, the lead investigator of the study. “While therapies for breast cancer are increasing, the treatment of drug resistance remains one of the clinical challenges. I am feeling excited about the coming Phase III study of afuresertib in breast cancer”.
Share:
More News
Lamine Mbow, Global Head of Discovery Research, Boehringer Ingelheim, said: “We are building a broad pipeline of ADCs addressing novel tumor target space to develop next-generation cancer treatments. By combining our deep expertise in cancer treatment development with Synaffix’s clinical-stage platform technology, we aim to accelerate the delivery of first-in-class
“The initial therapy of high-risk, non-muscle invasive bladder cancer with BCG has not advanced in decades. Today’s pivotal Phase 3 CREST results are potentially practice-changing, representing the first advance in therapy for BCG-naïve, high-risk, non-muscle invasive cancer in over 30 years,” said Roger Dansey, M.D., Chief Oncology Officer, Pfizer. “These
“Receiving FDA IND clearance is an important milestone in the advancement of TYRA-300 and for patients with NMIBC who urgently need better tolerated therapeutic options,” commented Doug Warner, Chief Medical Officer of TYRA. “We look forward to leveraging Erik’s impressive background to guide our development plans in NMIBC. We expect
“As a leader in hematologic malignancies, AbbVie is committed to advancing innovative treatments for complex cancers like multiple myeloma through our relentless R&D efforts and collaborations,” said Mariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. “We look forward to partnering with Simcere Zaiming, to advance
